These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 33350473)
1. Circulating heparin-like anticoagulants: Case report and review of literature. Hou C; Moffat KA; Gangji AS; Ning S Transfusion; 2021 Mar; 61(3):968-973. PubMed ID: 33350473 [TBL] [Abstract][Full Text] [Related]
2. Mycophenolate mofetil (MMF) for the treatment of steroid-resistant idiopathic thrombocytopenic purpura. Hou M; Peng J; Shi Y; Zhang C; Qin P; Zhao C; Ji X; Wang X; Zhang M Eur J Haematol; 2003 Jun; 70(6):353-7. PubMed ID: 12756016 [TBL] [Abstract][Full Text] [Related]
3. AGA Clinical Practice Update: Coagulation in Cirrhosis. O'Leary JG; Greenberg CS; Patton HM; Caldwell SH Gastroenterology; 2019 Jul; 157(1):34-43.e1. PubMed ID: 30986390 [TBL] [Abstract][Full Text] [Related]
4. Mycophenolate mophetil therapy for chronic immune thrombocytopenic purpura resistant to steroids, immunosuppressants, and/or splenectomy in adults. Colović M; Suvajdzic N; Colović N; Tomin D; Vidović A; Palibrk V Platelets; 2011; 22(2):153-6. PubMed ID: 21142405 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of mycophenolate mofetil as single-agent therapy for refractory immune thrombocytopenic purpura. Provan D; Moss AJ; Newland AC; Bussel JB Am J Hematol; 2006 Jan; 81(1):19-25. PubMed ID: 16369979 [TBL] [Abstract][Full Text] [Related]
6. Retrospective analysis of rituximab therapy and splenectomy in childhood chronic and refractory immune thrombocytopenic purpura. Ay Y; Karapinar TH; Oymak Y; Toret E; Demirag B; Ince D; Ozcan E; Moueminoglou N; Koker SA; Vergin C Blood Coagul Fibrinolysis; 2016 Jun; 27(4):431-5. PubMed ID: 26656905 [TBL] [Abstract][Full Text] [Related]
7. [Treatment of chronic idiopathic thrombocytopenic purpura with small dose heparin: a report of 12 cases]. Wang MF; Li MY; Wu GS Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2002 Jun; 10(3):251-2. PubMed ID: 12513797 [TBL] [Abstract][Full Text] [Related]
8. Randomized trial of anti-D immunoglobulin versus low-dose intravenous immunoglobulin in the treatment of childhood chronic idiopathic thrombocytopenic purpura. El Alfy MS; Mokhtar GM; El-Laboudy MA; Khalifa AS Acta Haematol; 2006; 115(1-2):46-52. PubMed ID: 16424649 [TBL] [Abstract][Full Text] [Related]
10. Mycophenolate mofetil as a treatment for refractory idiopathic thrombocytopenic purpura. Zhang WG; Ji L; Cao XM; Chen YX; He AL; Liu J; Zhao WH; Zou SP Acta Pharmacol Sin; 2005 May; 26(5):598-602. PubMed ID: 15842780 [TBL] [Abstract][Full Text] [Related]
11. Life-threatening hypercoagulable state following splenectomy in ITP: successful management with aggressive antithrombotic therapy and danazol. Tiede MP; Ahn ER; Jy W; Scagnelli T; Bidot CJ; Horstman LL; Jimenez JJ; Ahn YS Clin Appl Thromb Hemost; 2005 Jul; 11(3):347-52. PubMed ID: 16015423 [TBL] [Abstract][Full Text] [Related]
12. The PiCT Brisset AC; Ferrández A; Krause M; Rathbun S; Marlar R; Korte W J Thromb Haemost; 2016 Nov; 14(11):2187-2193. PubMed ID: 27582411 [TBL] [Abstract][Full Text] [Related]
13. Discordant Partial Thromboplastin Time (PTT) vs Anti-Xa Heparin Activity. Khan J; Chandler WL Am J Clin Pathol; 2019 Mar; 151(4):424-432. PubMed ID: 30475952 [TBL] [Abstract][Full Text] [Related]
14. Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy? Laux V; Perzborn E; Heitmeier S; von Degenfeld G; Dittrich-Wengenroth E; Buchmüller A; Gerdes C; Misselwitz F Thromb Haemost; 2009 Nov; 102(5):892-9. PubMed ID: 19888525 [TBL] [Abstract][Full Text] [Related]
15. The detection of changes in heparin activity in the rabbit: a comparison of anti-xa activity, thrombelastography, activated partial thromboplastin time, and activated coagulation time. Nielsen VG Anesth Analg; 2002 Dec; 95(6):1503-6, table of contents. PubMed ID: 12456408 [TBL] [Abstract][Full Text] [Related]
16. Competition of unfractionated heparin and idraparinux on activated partial thromboplastin time and effect of exogenous antithrombin. Gouin-Thibault I; Samama MM Thromb Haemost; 2009 May; 101(5):986-7. PubMed ID: 19404557 [No Abstract] [Full Text] [Related]
17. Evaluation of Antifactor-Xa Heparin Assay and Activated Partial Thromboplastin Time Values in Patients on Therapeutic Continuous Infusion Unfractionated Heparin Therapy. McLaughlin K; Rimsans J; Sylvester KW; Fanikos J; Dorfman DM; Senna P; Connors JM; Goldhaber SZ Clin Appl Thromb Hemost; 2019; 25():1076029619876030. PubMed ID: 31530176 [TBL] [Abstract][Full Text] [Related]
18. [Severe thrombocytopenia after diagnosis of deep venous thrombosis]. Frøslev-Friis C; Kliment H; Andersen JD Ugeskr Laeger; 2013 Aug; 175(33):1875-7. PubMed ID: 23937877 [TBL] [Abstract][Full Text] [Related]
19. Refractory Heparin-Induced Thrombocytopenia With Cerebral Venous Sinus Thrombosis Treated With IVIg, Steroids, and a Combination of Anticoagulants: A Case Report. Gonzales M; Pipalia A; Weil A J Investig Med High Impact Case Rep; 2019; 7():2324709619832324. PubMed ID: 30939936 [TBL] [Abstract][Full Text] [Related]
20. Anti-factor Xa and activated partial thromboplastin time measurements for heparin monitoring in mechanical circulatory support. Adatya S; Uriel N; Yarmohammadi H; Holley CT; Feng A; Roy SS; Reding MT; John R; Eckman P; Zantek ND JACC Heart Fail; 2015 Apr; 3(4):314-22. PubMed ID: 25770404 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]